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Our purpose was to determine pediatric endocrinologists’ knowledge, attitudes, beliefs, and practices (KABPs) regarding
recombinant human growth hormone (rhGH) treatment, examine care-related attitude consensus or discordance, and identify
evidence-based practice gaps. We developed a survey for National Cooperative Growth Study (NCGS) investigators (N = 711) to
elicit their KABPs regarding GH stimulation testing as a diagnostic tool, IGF-1 monitoring for safety and dosing guidance, and
pubertal dosing. Responses were compared with NCGS data from the last 20 years. Comparison between survey responses and
NCGS data revealed potential discrepancies between expressed opinions and actual practice. In conclusion, this KABP survey,
combined with NCGS data, suggests changes over time in diagnostic and rhGH-related therapeutic practices. Variability and
inconsistency exist between the survey responses and practice trends over time as reﬂected in the NCGS database. Further study is
necessary to provide evidence to guide rhGH treatment decisions.
1.Introduction
Therapy with growth hormone, initially derived from
cadaveric human pituitary glands, began in the late 1950s
and expanded with the availability of recombinant human
growth hormone (rhGH) in1985. rhGH therapy for growth
disorders in children and, more recently, for replacement
or anabolic actions in adults, has been prescribed and
monitored primarily by endocrinologists and nephrologists.
Prescribing and monitoring practices have evolved over
time based upon the availability of rhGH, hormonal assays,
and experience in the treatment of an expanding list of
indications. However, the ongoing debates regarding diag-
nostic and treatment paradigms, and the changing practice
guidelines and their interpretation by third-party payers,
emphasize the lack of extensive evidence for our current
practices. In order to improve the care of children with
growth disorders, we sought to identify speciﬁc areas in
which evidence suggests a need for further study and in
which there is great variability in clinical practice. The
objectives of our eﬀorts were to determine attitudes and
beliefs of pediatric endocrinologists regarding treatment
of children receiving rhGH, examine areas of consen-
sus and discordance in attitudes related to care delivery,2 International Journal of Pediatric Endocrinology
and identify gaps in evidence-based practice for quality
improvement. In order to achieve this goal, the Knowledge
Attitudes Beliefs Practice (KABP) process was utilized.
First, an analysis of the literature regarding GH treatment
of children and adolescents using methods described by
the Cochrane collaboration was performed to assess exist-
ing evidence-based practice recommendations and treat-
ment guidelines (Knowledge) [1]. We then developed a
survey based upon existing evidence gaps and surveyed
investigators participating in the phase 4 postmarketing
safety surveillance trial, the National Cooperative Growth
Study (NCGS), to determine current opinions regarding
treatment processes (Attitudes and Beliefs). In order to
evaluate how Attitudes and Beliefs are translated into
clinical practice, we compared the survey responses to actual
practice based upon data entered into the NCGS registry
(Practice).
The NCGS database has enrolled 55,000 children treated
with Genentech rhGH products in North America between
the years 1987 and 2005. The purpose of the database was
to gather safety and eﬃcacy data on the use of rhGH in
the postmarketing setting. Because of the large number
of children in the database, the relative risk of rare side
eﬀects can be estimated. In addition, the size of the study
provides suﬃcient patient information to aid in determining
the baseline and treatment factors that impact the growth
response in rhGH-treated children.
2. Methods
To develop the survey content, we reviewed the most
recent guidelines from the American Association of Clinical
Endocrinologists (AACE) [2], the Endocrine Society (ES)
[3], the Growth Hormone Research Society (GHRS) [4], and
the Lawson Wilkins Pediatric Endocrine Society (LWPES)
[5] and extracted speciﬁc recommendations for diagnosis
and treatment. In addition, a Medline search was con-
ducted on the terms “growth hormone,” “growth hormone
deﬁciency,” “Turner syndrome,” “craniopharyngioma,” and
“Prader-Willi syndrome.” The search was limited to papers
published since the most recent updates of the guidelines
(2003–2006). This search yielded 387 citations. The search
wasthenlimitedfurthertothosepapersthatincludedaspects
of care related to diagnosis of growth hormone deﬁciency
(GHD), growth hormone treatment initiation, dosing, mon-
itoring, and duration of therapy. This yielded 149 articles.
Articles were reviewed by teams of two, including a clinician
and an epidemiologist, using criteria established by the
Cochranecollaboration[1]. Articles were ranked on strength
of evidence and whether or not the conclusions supported
either a new or existing aspect of care as recommended by
guidelines [6].
Simultaneously, a panel of six academic pediatric
endocrinologists with special expertise in growth disorders
was recruited by members of the NCGS investigators’
advisory board. Results of the literature review were sum-
marized and disseminated to the panel, and a meeting
was convened in September 2006 to formulate the survey
content.AmodiﬁedRAND[7]approachwasusedtoidentify
and rank the relative importance of each aspect of care
to be included on the survey. Statements were developed
regarding care, and respondents were asked to rank their
level of agreement or disagreement with each statement.
The following is a sample question: “If it were not required
for reimbursement, I would continue to perform growth
hormone stimulation testing on my patients that I am
evaluating for GHD.” The respondent was asked to circle
a number ranging from 1 through 7, with 1 representing
“strongly agree,” 4 representing “agree,” and 7 representing
“strongly disagree.” Other questions necessitated picking a
singleanswerorrankingresponses.Theﬁnalsurveyincluded
questions on screening studies performed in short children,
criteria for screening, diagnosis of GHD, rhGH dosing,
monitoring,assessinggrowthresponse,determiningwhento
stop therapy, and reevaluating at adult height.
Surveys were mailed to all active principal investigators
and subinvestigators who had patients enrolled in the NCGS
registry (N = 711). Respondents were given return postage–
paid envelopes and asked to complete the surveys over a 6-
week period. Results were tabulated and data were analyzed
usingSPSS13.0(Chicago,IL).Forquestionsrequiringagree-
ment or disagreement percentage, respondents answering
with a value of 1 to 4 were considered to be in agreement,
and those responding with a value of greater than 4 were
considered to be in disagreement.
To facilitate comparison between survey data and clinical
practice, data were abstracted from the NCGS database.
Following obtainment of informed consent/assent, data for
rhGH-treated children are entered anonymously into the
database. Required data for initial enrollment include date
of birth, sex, pretreatment height and weight, pubertal
staging, diagnosis (according to investigator), rhGH dosage,
and start date of therapy. Required data from subsequent
clinic visits include date of visit, height, weight, pubertal
staging, and dosage prescribed at the visit. Optional data
such as parental heights, birth weight, previous growth
measurements, concomitant medications, bone age results,
insulin-like growth factor 1 (IGF-1) levels, thyroid function,
andresultsofgrowthhormoneorotherpituitarytestingmay
also be entered. For the purposes of this analysis, data were
analyzedfromthetimethattheNCGSwasrolledouttomost
major endocrine sites (1987), and for the most recent 5-year
period.
Statistical analyses were performed at the 5% signiﬁ-
cance level using two-sided tests. Quantitative variables are
summarized using means, standard deviation scores (SDS),
and Student’s t-test where appropriate. Qualitative variables
are summarized using number of nonmissing data, counts,
percentages, and χ2 test where appropriate.
3. Results
3.1. Strength of Evidence in Literature. Articles (n = 140)
were ranked on strength of evidence and whether or not the
conclusions supported either a new or existing aspect of care
as recommended by guidelines (Table 1)[ 1, 6].International Journal of Pediatric Endocrinology 3
Table 1: Characteristics of articles reviewed.
N = 149
Evidence Type %
Randomized controlled trials (large) 5
Randomized controlled trials (small) 21
Nonrandomized trials 13
Case studies/series 19
Observational studies 39
Expert opinion 3
Evidence Strength∗ %
Level 1 (a–c) 5
Level 2 (a–c) 27
Level 3 (a–b) 24
Level 4 39
Level 5 5
∗Level 1 (a-c): systematic reviews, large randomized controlled trials; Level
2 (a-c): small or underpowered clinical trials, cohort studies; Level 3 (a-b):
case control studies, other epidemiology or outcomes studies; Level 4: case
series; Level 5: expert opinion. Articles reviewed available in Supplemental
Reference List.
Table 2: Characteristics of survey respondents.
N = 207
Age (mean, range) 52 (31–77)
Gender
Male, % 58
Specialty
Pediatric endocrinology, % 95
Nephrology, % 2
Other, % 3
Private practice, % 37
Teaching medical students, % 91
Board certiﬁed, % 88
Years in practice
0–5 years, % 11
6–10 years, % 12
11–15 years, % 19
16–20 years, % 15
> 20 years, % 43
Years prescribing growth hormone-mean (range) 17 (3–40)
Current number of treated patients-mean (range) 95 (8–500)
3.2. Demographics. Of 711 surveys mailed to NCGS inves-
tigators, 207 (29%) were returned by the deadline for
analysis. A total of 260 surveys were eventually returned
(37% response rate). This response rate is comparable to
a 2007 survey of LWPES members used to guide organi-
zational priorities (33%, personal communication LWPES
oﬃce). Respondents were primarily board-certiﬁed pediatric
endocrinologists (Table 2) involved in teaching medical
students. The mean age of respondents was 52 years, with
a signiﬁcant proportion (43%) in practice for more than 20
years.
3.3. Screening the Poorly Growing Child. Most clinicians
strongly agreed that an initial evaluation should occur at
height ≤− 2.0 SDS (82%) or ≥1.5 SDS below midparental
height SDS (87%). Review of entry height for children in the
NCGS database treated with rhGH for all etiologies of short
stature shows that 75% had an initial height ≤− 2.0 SDS,
with a mean entry height of −2.6 SDS.
With regard to initial laboratory evaluation in the poorly
growing child, 95% of respondents endorsed obtaining a
bone age radiograph and thyroid functions; 94%, serum
IGF-1 levels; 91%, chemistry panel; 87%, a karyotype in
females. A complete blood count, IGF-binding protein 3
(IGFBP-3), urinalysis, sedimentation rate, and screening for
celiac disease were included by 75% to 85% of respondents.
AnalysisoftheNCGSdatarevealsthatabone ageradiograph
(76%) is the most common screening test recorded for all
children entered in the study. IGF-1 (24%) and IGFBP-3
(16%) are the next most common screening tests recorded.
3.4. Diagnosis of GHD. Seventy percent of all children
entered into NCGS since 1987 are recorded as having
undergone growth hormone stimulation testing (GHST).
This fraction has been steadily decreasing over time, with
only 53% recorded as having undergone GHST during
the period from 2000 to 2005 (Table 3). Even in children
diagnosed with organic GHD, the rate of GHST recorded
has declined from 74% overall to 49% from 2000 to 2005.
GHST use in children with Turner syndrome and children
diagnosed as small for gestational age without catch-up
growth has declined to minimal use (Table 3).
According to the survey, 18% of clinicians continue to
routinely use the insulin tolerance test (ITT). The recorded
use of the ITT in NCGS has also declined over time (29% of
all patients since 1987; 20% between 2000 and 2005).
Respondents felt that GHST was not necessary prior
to initiating rhGH therapy in a poorly growing child with
documentation of either a structural pituitary abnormality
or a known hypothalamic pituitary insult (i.e., radiation,
surgery, or trauma; 21%), low serum IGF-1 (for age, gender,
and sexual maturation; 2%), or both (33%). Thus, a total of
56% of respondents felt there were circumstances in which
GSHTwasnotnecessarypriortorhGHtherapy.Twenty-nine
percent felt that GHST should always be performed when
considering the diagnosis of GHD. Survey respondents who
had been practicing pediatric endocrinology for 16 or more
years or longer were signiﬁcantly more likely to report that
GHST should always be performed than those who had been
practicing for 15 or fewer years (37% versus 21%, P<. 05).
When asked what criteria would be necessary to make
a diagnosis of GHD if GHST was not required by payers,
57% felt that GHST was necessary to make a diagnosis of
GHD, and 55% reported they would continue to perform
GHST. Despite this response, low serum IGF-1, low growth
velocity, magnetic resonance imaging (MRI) evidence, low
IGFBP-3, and low height were all ranked higher than GHST
as requirements for making a diagnosis of GHD (Figure 1).
Eighty-two percent answered that a low level of serum
IGF-1, in the absence of malnutrition and chronic illness,4 International Journal of Pediatric Endocrinology
Table 3: Use of GHST and IGF-1 testing reported in the NCGS registry.
All years N = 51,909 2000–2005 n = 16,481
Stimulation test performed, % 70 53
Stimulation testing only performed, % 50 18
Stimulation testing performed with IGF-1, % 20 35
IGF-1 test performed, % 24 41
IGF-1 test performed in absence of stimulation testing, % 4 6
Stimulation test performed with insulin, % 29 20
GHST: growth hormone stimulation test; IGF-1: insulin-like growth factor 1; NCGS: National Cooperative Growth Study.
Strongly agree Agree Strongly disagree
1234567
Low IGF-1 for age and gender ∗,†,‡
Growth velocity < 25th percentile for age
MRI∗,†,‡
IGFBP3 low for age and gender∗,†,‡
Height < −2 SDS [or 3rd percentile]∗,†,‡
Growth hormone stimulation testing∗,‡
90% agree
83% agree
65% agree
70% agree
65% agree
57% agree
8% disagree
14% disagree
28% disagree
26% disagree
31% disagree
36% disagree
∗GH research society,† AACE,‡ LWPES
Indicates mean response, shading represents density of responses,
proportion indicate those responding 4 or greater
Figure 1: Responses to the survey question: “Assuming stimulation testing is not required by payers, the following are necessary to make
a diagnosis of GHD.”
was equivalent to (45%) or better than (37%) GHST. Those
in nonteaching settings were signiﬁcantly more likely than
those in teaching settings to have this opinion (100% versus
82%, P<. 05). There was no statistical diﬀerence based upon
years in practice. Diagnostic measurement (and recording in
NCGS) of serum IGF-1 in children with short stature of all
etiologies has increased over time (24% all years, 41% 2000–
2005), but its use as an exclusive diagnostic tool in GHD is
seen only in a small number of patients in the database (4%
all years, 6% 2000–2005; Table 3).
3.5.MonitoringSerumIGF-1DuringrhGHTherapy. Routine
measurement of serum IGF-1 levels has been proposed for
both safety and eﬃcacy monitoring [8]. In our survey,
respondents endorsed measuring serum IGF-1 routinely
(72%) and making rhGH dose adjustments to maintain
the IGF-1 in the midnormal (66%) or high-normal (55%)
range. However, more common reasons for dose adjustment
were growth response (85%) and weight (80%). In addition,
22% would measure serum IGF-1 only when patients were
responding poorly. In patients with elevated serum IGF-1,
55% reported that they would decrease the rhGH dose, 28%
would make no change, and 15% reported that they do not
use serum IGF-1 to adjust therapy. Analysis of NCGS data
suggests that in actual practice only 41% of children have an
IGF-1 recorded on at least an annual basis.
3.6. Assessing Response to rhGH Therapy. Eighty-seven per-
cent of the survey participants responded that they would
always determine growth velocity prior to initiation of
rhGH therapy. However, pretreatment growth velocity was
recorded for only 48% of children entered into the NCGS
database. When asked what constituted a poor response to
rhGH therapy, the least stringent and most easily measured
minimal response, an increase of <2cm/year over baseline,
was most popular (85%) among respondents. Slightly fewer
indicated that an increase of <0.25 height SDS/yr (78%)
and <50% increase in growth velocity over baseline (77%)
were reasonable criteria. When asked what the duration
of an adequate trial of rhGH therapy should be, most
considered assessing adequacy of growth response after 3
(40%) or 6 (50%) months of therapy. This reported practice
is supported by the ﬁrst documented entry of treatment
response data into NCGS at 3 (65%) and 6 (20%) months.
If the growth response to rhGH therapy is deemed
inadequate in a patient, most (86%) responded that theyInternational Journal of Pediatric Endocrinology 5
woulduseserumIGF-1levelstoguidetheirdecisionwhether
to increase the rhGH dose or stop therapy. Many (69%)
would increase the rhGH dose. Most (66%) disagreed with
stopping treatment based upon a poor growth response
alone.
To compare these reported decision points to practice,
we analyzed the ﬁrst-year growth response of children with
GHD or idiopathic short stature (ISS, short stature with
no evidence of illness, and normal GHST) in the NCGS
database. Among those who had a recorded pretreatment
growth velocity, 11% of GHD patients and 12% of ISS
patients had a ﬁrst-year increase of <2cm/yr, 13% of both
groups had an increase of <0.25 height SDS/yr, and 16% of
both groups had <50% increase in growth velocity. More
than 40% of children who had a poor growth response,
as deﬁned by any of the three criteria listed above, were
continued on the same dose of rhGH therapy. This was the
case for children with GHD whether or not a serum IGF-
1 was recorded. However, if an IGF-1 level was recorded
for children with ISS, the dose of rhGH was more likely to
be increased (64%) than for children in whom it was not
recorded (47%, P<. 05).
3.7. Pubertal Dosing. To assess the impact of the study of
Mauras et al. [9], which reported the results of an increase
in the dose of rhGH during puberty to 0.7mg/kg/week, a
dose that was subsequently approved by the U.S. Food and
Drug Administration (FDA) in 2000, we asked if survey
respondents felt that rhGH dosing should be increased in
all pubertal patients with GHD (35% agreed) or if the
increase should be reserved for those who are not expected
t or e a c ht a r g e th e i g h t( 5 9 %a g r e e d ) .T h eN C G Sr e g i s t r y
data support the survey results: 37% of patients received
rhGH doses >0.4mg/kg/wk during puberty (Tanner stages
2–4). Only 10% were prescribed the 0.7mg/kg/week dose.
The degree of short stature did not appear to impact the
decision, as frequency of pubertal dosing was not increased
in children whose height was < −2 SDS. Similar percentages
of respondents (56%) felt that pubertal dosing should be
used in pubertal-age children with ISS who are not expected
to reach target height. Twelve percent stated that pubertal
dosing should rarely, if ever, be used in ISS, whereas no
respondents expressed this opinion for the diagnosis of
GHD.
3.8.EndofrhGHTherapy. Surveyedphysicianswereaskedto
rank factors that were considered important in the decision
to end rhGH therapy. Documentation of epiphyseal closure
was ranked ﬁrst by 39%. Continuation of rhGH treatment
until the patient was comfortable with height and slowed
growth velocity to <2cm/yr were ranked ﬁrst by 23% and
21% of respondents, respectively, and had an identical rank
mean score (3.0). In the NCGS database, an explanation
for discontinuation of rhGH was provided for only 7% of
children; of this small group, 86% were still growing at least
2cm/yr, 82% were within 2 SDS of target height, 60% were
>5th percentile for adult height, and only 13% were near
epiphyseal closure (bone age >15 years in girls, >17 years in
boys) (Table 4).
3.9. Treatment into Adulthood for the GHD Adolescent.
GHD in adults is an indication for rhGH therapy. Figure 2
illustrates the response to a question regarding cessation of
therapy and the need for diagnostic retesting. When asked
if rhGH should be stopped in adolescents with idiopathic
GHD when growth is complete, 74% respondents indicated
that they would stop treatment. Eighty-four percent agreed
with continuing therapy if repeaingt GHST reveals a peak
GH response of <5ng/mL. Fifty-ﬁve percent would continue
therapy based upon a low serum IGF-1 level alone (following
temporary cessation of GH treatment). In children with
multiple pituitary hormone deﬁciencies, 84% agreed that
rhGH treatment should continue without interruption.
Table 5 summarizes the comparison of the published
clinical practice guidelines, survey responses, and NCGS
registry data for each clinical question.
4. Discussion
This study uses the KABP process to identify current gaps in
the evidence for clinical care in rhGH therapy (Knowledge),
determine the opinions of a group of rhGH prescribers
(Attitudes and Beliefs), and compare the opinions reﬂected
by that survey to data entered into an rhGH safety and
eﬃcacy registry (NCGS) with voluntary data ﬁelds (Prac-
tice). The goal was to identify speciﬁc areas of clinical
practice variability that may identify areas of consensus
and disagreement where evidence-based data are lacking to
provide a basis for future knowledge development which
could improve care of children treated with rhGH.
Respondents to the survey, 29% of NCGS investigators,
were largely experienced, board-certiﬁed endocrinologists
who held teaching positions and were members of the
LWPES. Although this is a low survey response rate, a similar
2007 survey of LWPES members yielded a similar response
rate. In addition, the demographics of our survey were
similar to the 2007 LWPES survey except that our study
had a slightly higher rate of responders in private practice
(37 versus 24%), fewer responders in practice >20 years (43
v e r s u s5 5 % ) ,a n dm o r er e s p o n d e r si np r a c t i c e<5 years (11%
versus 4%). However, regardless of the demographics, due
to the low response rate, the responses described may not
accurately reﬂect the opinions of all NCGS investigators or
the larger pediatric endocrinology community.
The use of the NCGS database to reﬂect current and
previous practice may not reﬂect practice in all children
receiving rhGH during this period. Estimates based upon
the number of children receiving rhGH products eligible
for enrollment in the study who have data entered and
the market share of these products suggest that NCGS data
reﬂect approximately 30% of nearly 200,000 children treated
with rhGH since its approval in 1985. In addition, NCGS
data may not be a complete and accurate reﬂection of
practice in those children entered into the database due to
the absence of potentially relevant data. However, the NCGS6 International Journal of Pediatric Endocrinology
∗13% of physicians did not provide a response
Stop rhGH and measure IGF-1 after at least one month
Stop rhGH and perform an IGF-1 and a growth hormone stimulation test
Stop rhGH and refer to an adult endocrinologist
Stop rhGH and perform a growth hormone simulation test
Stop rhGH and evaluate body composition then repeat the evaluation again in 6 months
Don’t stop rhGH, but i refer the adolescent to an adult enocrinologist
Strongly agree Agree Strongly disagree
1234567
74% agree
60% agree
40% agree
39% agree
36% agree
36% agree
10% agree
14% disagree
30% disagree
47% disagree
49% disagree
51% disagree
53% disagree
76% disagree
Stop rhGH treatment
Indicates mean response, shading represents density of responses,
proportion indicate those responding 4 or greater
Figure 2: Responses to the survey question: “In idiopathic isolated GHD adolescents who are at the end of linear growth, I generally....”
Table 4: Factors inﬂuencing decision to discontinue a course of rhGH.
Rank (mean score) N = 207 Proportion ranked as #1 N = 207
Epiphyseal closure is documented 1 (2.5) 39%
Patient is comfortable with his/her height 2∗ (3.0) 23%
Patient’s growth velocity is <2cm/yr 2 ∗ (3.0) 21%
Patient’s growth velocity is <1cm/yr 4 (3.1) 12%
Patient is at least at the 5th percentile for adult population 5 (4.6) 4%
Patient is within two SDs of target height 6 (4.7) 2%
rhGH: recombinant human growth hormone; SD: standard deviation.
∗Indicates a tie.
is the largest data repository for rhGH therapy in children
i nt h eUSF u r t h e r m o r e ,m e a s u r e so fp r a c t i c em a yn o t
reﬂect attitudes, beliefs, and opinions due to insurance
requirements.
4.1. Screening Poorly Growing Children and Diagnosis of
GHD. The survey consensus was that children should be
screened for GHD when height is < − 2.0SDS (or >1.5SDS
below midparental height). This consensus is consistent with
current practice guidelines [1, 3, 4] and is supported by the
characteristics of children enrolled in NCGS (mean height
SDS −2.6, 75% < −2.0SDS). In addition to screening
for GHD, the initial evaluation of children with short
stature is targeted to identify any chronic illness that could
potentially aﬀect growth. Survey responders endorsed the
following screening tests most strongly: baseline growth
velocity, bone age, thyroxine, TSH, IGF-1, chemistry panel,
and karyotyping for girls. In a previous study of pediatric
endocrinology practices [10], these screening tests had a
similar rank order of use. However, the actual frequency of
these tests on the initial visit was reported to be signiﬁcantly
lower even in children with severe short stature (height SDS
< −3.0SDS and/or < −1.5SDS below midparental height).
It was also observed that most children never returned for a
r equest edsec ondvisit[10].Thelatterﬁndingemphasizesthe
importance of obtaining screening laboratory studies at the
initial visit and/or stressing the importance of followup visits
to determine the growth velocity [11].
How or whether to make a diagnosis of GHD prior to
initiating therapy remains an area of controversy. Accurate
diagnosis of GHD is crucial to the identiﬁcation of children
who are at risk of having or developing other pituitary
hormone deﬁciencies, in particular adrenal insuﬃciency
[12]. Current guidelines include short stature with poor
growth velocity, low GH peak following GHST, low serum
IGF-1 and IGFBP-3, and delayed bone age as typical features
of GHD, with GHST remaining the gold standard [2–5].
The combination of poor height velocity and low IGF-1 has
also been shown to correlate well with GHD [13]. However,
the use of a combined approach including GHST, IGF-1,
and IGFBP-3 levels improves speciﬁcity of GHD diagnosis
[14]. The use of GHST, and particularly ITT, has declined
over time [15]. The reasons for decreased use of GHST may
includealackofreproducibility,lackofpersonneltoperform
the test, confounding inﬂuence of pubertal stage and body
mass index, expense, and safety risk [15–17].International Journal of Pediatric Endocrinology 7
Table 5: Comparison of published clinical practice guidelines, survey responses, and NCGS registry data.
Clinical question Guidelines Survey response NCGS data
Height SD prompting
evaluation of GHD
< −3a, < −2.25b, < −2c < −2S D
plus GV < −1S D
a,c >1.5 SD than
MPH
a,c >2S Dt h a nM P H
b
< −3 SD 88% < −2 SD 82% >1.5
SD below MPH 87%
At start of treatment < −2S D
75%
Is GHST necessary to
make diagnosis of GHD?
GHST <10mcg/L plus IGF-1
< −2 SD important for
diagnosisa. GHST optional if
structural pituitary lesion,
surgery, radiation, or MPHD
b.
GHST should always be
performed (29%).
In presence of structural
abnormality or pituitary insult
plus low IGF-1, GHST not
necessary (33%).
Recorded GHST
All Patients 1987−2005 70%
2000−2005 53%
OGHD Patients 1987−2005 74%
2000−2005 49%
If not required by
insurance would you
continue to perform
GHST?
Important for diagnosis of
GHD
a. 55% would still perform GHST N/A
Value of IGF-1 in
diagnosis of GHD
< −2 SD required
a.
< −2 SD strongly suggestivec.
GHD unlikely if IGF-1 ≥0S D
b.
Low IGF-1 in absence of disease
and malnutrition equivalent
( 4 5 % )o rb e t t e r( 3 7 % )t h a n
GHST.
Recorded IGF-11987−2005 24%
2000−2005 41%IGF-1 sole
diagnostic tool recorded in
4%−6%
Routine monitoring of
IGF-1 on GH therapy
Monitoring of IGF-1 is useful
a.
Yearly monitoring of IGF-1 is
useful
b.
If IGF-1 > +2 SD after ﬁrst two
years of therapy, GH dose
reduction should be considered
b.
72% endorse routine monitoring
of IGF-1.
Growth response (85%) and
weight gain (80%) were more
commonly endorsed as basis of
GH dose adjustments than IGF-1
targets (55%−62%).
86% endorsed use of IGF-1 to
guide GH dose increase if growth
response is poor.
41% have IGF-1 recorded at least
annually (2000−2005).
GH dose was more likely to be
increased in ISS patient growing
poorly in the ﬁrst year of therapy
if IGF-1 was measured.
No impact of IGF-1
measurement on GH dose
increase in IGHD or OGHD
poor responders.
Assessing response to
GH therapy
Height should increase > +0.25
SD in ﬁrst yearb.
GH dose increase may be
considered if compliance and
o t h e rc a u s e so fp o o rg r o w t h
eliminated
b.
Poor response criteria (% agree)
< +0.25 Height SD (78%)GV
increase of <2cm/yr (85%)
<50% GV increase (77%)
Poor response rate< +0.25
Height SD (13%)
GV increase of <2cm/yr
(11%)<50% GV increase (16%)
No dose change made in >40%
of poor responders (IGHD or
OGHD).
Use of Pubertal dosing
GH at a dose of 0.7mg/kg/wk
increased near adult height by 4
cm (0.7 SD) compared to
0.3mg/kg/wk dosec.
Pubertal dosing should be used:
in all GHD patients (35% agree);
only in patients not expected to
reach target height (59% agree)
GH Dose during puberty
>0.4mg/kg/wk
37% >0.6mg/kg/wk 10%
Height < −2 SD was not more
common among those receiving
these higher GH doses.
Transition evaluation
Repeat GHST not necessary if
MPHD, severe organic GHD, or
genetic defectsa,b.
Re-evaluate with GHST
a,b and
IGF-1a 1−3m o n t h sa f t e r
stopping GH.
In children with MPHD GH
need not be discontinued (84%
agree); would resume GH with
ﬁnding of low IGF-1 alone after
stopping GH therapy for at least
a month (55% agree).
N/A
GRSa;L W P E S b;A A C E c.
In our survey, there was general agreement that a low
IGF-1 for age, gender, and pubertal status in the absence of
malnutrition or chronic illness was equal to or better than
GHST.However,nearlyathirdofrespondentsfeltthatGHST
should always be performed, and more than half would
continue to perform GHST in order to make a diagnosis
of GHD even if not required by third-party payers. Despite
someevidenceimpugningthevalidityofGHSTduetoahigh
false-positive rate, this mixture of opinions likely reﬂects the
lack of a deﬁnitive alternative for the diagnosis of GHD.
Another confounding issue is that interpretation of serum
IGF-1 values remains diﬃcult because of the lack of assay
standardization and normative data for each current assay
for each age and stage of puberty [18]. Currently, there is8 International Journal of Pediatric Endocrinology
no single test that can consistently diﬀerentiate ISS from
idiopathic GHD [19]. This continues to be an area that
requires investigation.
Because of the low false-negative rate for GHST, it
has been reported that children with a normal response
to GHST do not require any further pituitary evaluation
[19]. However, following diagnosis of GHD based upon
an abnormal GHST, it has been recommended that further
functional testing of pituitary function and a brain MRI be
performed [2, 4]. Brain MRI with focus on the pituitary
has been proposed as an alternative to GHST for diagnosis
of GHD [20]. Pituitary MRI has been shown to be more
predictive than GHST of need for rhGH replacement in an
adult [21]. In our survey, 65% of respondents indicated that
an MRI was a necessary test for the diagnosis of GHD if
GHST was not required.
4.2. Response to rhGH Therapy. Increased growth rate is
the most commonly measured response to rhGH therapy.
However, an adequate response, compared with an accurate
pretreatment growth velocity, had not been deﬁned at the
timeofthissurvey.Publishedconsensustreatmentguidelines
have provided various metrics that have been adopted.
Our survey respondents endorsed the use of an increase
of >2cm/yr over baseline growth velocity. The minimum
duration of such a trial or the earliest point at which
to judge the clinical response remains unclear. Because of
the variability of growth and measurement error, it has
been proposed that the minimum interval between growth
measurements used to assess the response should be at least
6 months [22]. Recently, in an eﬀort to identify expected
growth response to rhGH therapy in the ﬁrst year of therapy
in children diagnosed with GHD, further analysis of NCGS
data was performed to establish growth velocity response
curves[23].Thispaperprovidesreferencedataagainstwhich
to compare a child’s ﬁrst-year growth velocity on treatment
and which may be used to assess compliance, accuracy
of diagnosis, the need for dose adjustment, consideration
of concomitant illness, or discontinuation of therapy. The
authors proposed that a response >1SD below the mean
for age and diagnosis should be considered a suboptimal
response.
4.3. Monitoring Serum IGF-1 during rhGH Therapy.
Although most investigators in our survey support meas-
uring serum IGF-1 during therapy, this test was fre-
quently not entered into the NCGS database. In addition,
many investigators did not act upon the IGF-1 values
obtained. This ﬁnding suggests that once rhGH therapy
has been initiated, physicians are reluctant to discontinue
it despite a lack of demonstrated response. A recent study
demonstrated that adjusting rhGH doses to the target IGF-1
at +2 SDS regardless of growth rate led to improved growth
response in the ﬁrst year of therapy in some children, while
others responded as well at lower IGF levels [24]. The
authors concluded that some combination of growth rate
and IGF targeting might be applicable. In addition, the safety
of IGF targeting, which may require very high rhGH doses in
some children, remains to be determined and that the use of
serum IGF-1 to adjust rhGH doses should be individualized
based upon the condition, age, pubertal status, and growth
response [25, 26].
4.4. Pubertal Dosing. Mauras et al. [9] demonstrated signiﬁ-
cant improvement in growth response in pubertal children
with GHD given higher doses of rhGH (0.7mg/kg/week).
Our survey suggests that since the publication and associated
U.S. FDA approval of pubertal dosing of Nutropin/Nutropin
AQ in GHD patients, many pediatric endocrinologists
endorse using higher rhGH doses during puberty, partic-
ularly in children not expected to reach expected height.
Analysis of the NCGS data documents higher doses used in
pubertal patients since the publication and FDA approval
of pubertal dosing, but the severity of short stature did not
appear to impact this practice. Although these results suggest
increased acceptance and use of pubertal dosing, they do not
validate it.
4.5.EndofTherapy. Whendeterminingtherighttimetostop
rhGH therapy, physicians usually consider growth velocity,
skeletal maturation, patient comfort with height, severity
of GHD, and the presence of other pituitary hormone
deﬁciencies. Survey respondents ranked epiphyseal fusion
before patient comfort with height and growth velocity
<2cm/yr,althoughtheNCGSdatasuggestthatmostpatients
were stopped before they had stopped growing. Although
the data set is small, it suggests that in practice rhGH
therapy is discontinued before cessation of growth and that
discontinuation may be due to factors other than satisfaction
with height, including the adolescent’s desire to end therapy.
In children with multiple pituitary hormone deﬁciencies
who have reached adult height, respondents agreed that no
retesting was necessary to continue rhGH. This corresponds
with recent publications showing that the incidence of
adult GHD increases with the number of other pituitary
hormone deﬁciencies [26]. There was no consensus about
the timing or methodology (serum IGF-1, GHST) necessary
for reevaluation of individuals diagnosed with isolated GHD
after achieving adult height.
4.6. Areas in Need of Evidence-Based Guidelines. The combi-
nationofthesurveyresponsesandtheircorrelationtoNCGS
data have helped to outline a number of areas of clinical
practice variability that require further investigation.
(1) Identiﬁcation of the best auxologic, imaging, and
biochemical proﬁle to diagnose GHD, predict risk of
multiple pituitary hormone deﬁciency, and predict
rhGH therapy response.
(2) Establishment of criteria to determine whether
growth response to rhGH therapy beyond the ﬁrst
year is adequate and likely to achieve maximal
increase in adult height.
(3) Assessment of the utility of monitoring IGF-1 for
long-term safety and eﬃcacy of rhGH therapy.International Journal of Pediatric Endocrinology 9
(4) Identiﬁcationofthebesttestandcutoﬀsfordiagnosis
of GHD requiring ongoing rhGH therapy after near-
adult height is attained.
5. Conclusions
The decision-making processes surrounding rhGH treat-
ment are based upon attitudes, beliefs, opinions, and per-
sonal experience of the physician. Outside of expert opinion
and data gathered for the approval of the current indications
for rhGH therapy in children, there are few evidence-based
studies to support these processes. The NCGS has been
an important resource for safety and eﬃcacy data and
can continue to be a data source to provide evidence for
development of future consensus guidelines. Our survey,
combined with analysis of NCGS data, has outlined several
areas that require further clinical study.
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